Clinical Trials on Moderate to Severe Systemic Sclerosis
Total 7274 results
-
Beer, Kenneth R., M.D., PAMedicis Pharmaceutical CorporationCompletedMild to Moderate Temporal Atrophy | Moderate to Severe Glabellar Rhytids | Moderate to Severe Periorbital RhytidsUnited States
-
Aqpha Medical B.V.Not yet recruitingModerate to Severe Nasolabial Fold
-
Daewoong Pharmaceutical Co. LTD.Completed
-
Galderma R&DCompletedModerate to Severe Glabellar LinesChina
-
EuBiologics Co.,LtdCompletedModerate to Severe Glabellar LinesKorea, Republic of
-
AllerganCompletedModerate to Severe Nasolabial FoldsGermany, Netherlands
-
IpsenCompletedModerate to Severe Glabellar LinesFrance, Germany
-
Daewoong Pharmaceutical Co. LTD.CompletedModerate to Severe Glabellar LineKorea, Republic of
-
JHM BioPharma (Tonghua) Co. , Ltd.Recruiting
-
AbbVieCompletedModerate to Severe Glabellar LinesJapan
-
Chongqing Claruvis Pharmaceutical Co., Ltd.CompletedModerate to Severe Glabellar LinesChina
-
Croma-Pharma GmbHCompleted
-
AllerganCompletedModerate to Severe Nasolabial FoldsUnited States
-
Merz North America, Inc.CompletedModerate to Severe Midface Volume DeficitCanada
-
Merz Pharmaceuticals GmbHCompletedModerate to Severe Glabellar Frown LinesUnited States, Canada
-
Kyowa Kirin Co., Ltd.Active, not recruitingModerate to Severe Systemic SclerosisJapan
-
Merz Pharmaceuticals GmbHCompletedModerate to Severe Glabellar Frown LinesUnited States
-
Merz Aesthetics GmbHMerz Pharmaceuticals GmbHCompletedModerate to Severe Glabellar Frown LinesUnited States, Germany
-
Croma-Pharma GmbHActive, not recruitingModerate to Severe Midface Volume DeficitUnited States
-
AllerganCompletedPatients With Moderate to Severe Perioral LinesUnited States
-
Xinhua Hospital, Shanghai Jiao Tong University...TerminatedASD Accompanied by Moderate to Severe Gastrointestinal SymptomsChina
-
Merz North America, Inc.CompletedCorrection of Moderate to Severe Nasolabial Folds (NLFs)China
-
Merz North America, Inc.CompletedCorrection of the Moderate to Severe Nasolabial FoldsChina
-
Astellas Pharma Europe Ltd.CompletedModerate to Severe Vasomotor SymptomsUnited Kingdom
-
Kythera BiopharmaceuticalsCompletedEfficacy | Safety | Moderate to Severe Convexity of Submental FatUnited States
-
Kythera BiopharmaceuticalsCompletedEfficacy | Safety | Moderate to Severe Convexity of Submental FatUnited States
-
PfizerCompleted
-
KoBioLabsNovotech (Australia) Pty LimitedCompletedModerate to Severe AsthmaAustralia
-
Merz North America, Inc.CompletedCorrection of Moderate to Severe Nasolabial FoldsUnited States
-
QRxPharma Inc.CompletedAcute Moderate to Severe PainUnited States
-
Egalet LtdCompletedModerate-to-severe Chronic Noncancer PainUnited States
-
Merck Sharp & Dohme LLCTerminatedWomen | Moderate to Severe Vasomotor Symptoms in Postmenopausal
-
Janssen PharmaceuticaWithdrawnModerate to Severe Acute Non-Cancer Pain
-
AbbottCompletedModerate to Severe Chronic, Non-malignant PainUnited States
-
BioPharmX, Inc.CompletedModerate to Severe Papulopustular RosaceaUnited States
-
Janssen PharmaceuticaWithdrawnModerate to Severe Chronic Non-cancer Pain
-
Mundipharma Research GmbH & Co KGCompletedSubjects With Moderate to Severe, Chronic Nonmalignant Pain
-
Actavis Inc.CompletedModerate to Severe Papulopustular RosaceaUnited States
-
Wake Forest University Health SciencesCompleted
-
Merck KGaA, Darmstadt, GermanyCompletedModerate to Severe PsoriasisSwitzerland
-
Merck KGaA, Darmstadt, GermanyCompletedModerate to Severe PsoriasisSwitzerland
-
PfizerCompletedModerate to Severe PsoriasisKorea, Republic of
-
Shanghai Junshi Bioscience Co., Ltd.CompletedModerate to Severe PsoriasisChina
-
Bristol-Myers SquibbTerminatedPsoriasis, Moderate to SevereUnited States
-
GC Cell CorporationRecruitingClinical Trial to Evaluate the Safety, Tolerability and Efficacy of CT303 in Patients With PsoriasisModerate to Severe Plaque PsoriasisKorea, Republic of
-
UCB Biopharma SRLActive, not recruitingModerate to Severe Plaque PsoriasisUnited States, Canada, Germany, Poland
-
TakedaNimbus Lakshmi, Inc.; Innovaderm Research Inc.CompletedModerate to Severe Plaque PsoriasisUnited States, Canada
-
BiocadCompleted
-
AbbVieCompleted
-
AbbVie (prior sponsor, Abbott)CompletedModerate to Severe Plaque PsoriasisRussian Federation